Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading ... (sigmoidoscopy score of less than or equa...)

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

Date:6/17/2008

sigmoidoscopy score of less than or equal to 1 with a sigmoidoscopy score reduction of greater than or equal to 1 point from baseline and no mucosal friability.

Important Safety Information for Lialda

Lialda tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of Lialda beyond eight weeks have not been established.

Lialda is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of Lialda. Caution should be exercised when treating patients with pyloric stenosis or those allergic to sulfasalazine. Mesalamine has been associated with an acute intolerance syndrome (three percent of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to distinguish from a flare of inflammatory bowel disease. If acute intolerance syndrome is suspected, prompt withdrawal is required.

Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported. Reports of renal impairment have been associated with mesalamine medications. In patients with renal impairment, caution should be exercised, and Lialda should be used only if the benefits outweigh the risks. No information is available for patients with hepatic impairment.

Lialda is generally well tolerated. The majority of adverse events in the double-blind, placebo-controlled trials were mild or moderate in severity. In clinical trials (n=535), the most common treatment-related adverse events with Lialda 2.4g/day, 4.8g/day and placebo were headache (5.6 percent, 3.4 percent and 0.6 percent, respectively) and flatulence (4 percent, 2.8 percent and 2.8 percent, respectively). Pancreatitis occurred in less than 1 percent of patients during clinical trials and resulted in discontinuation of therapy with Lialda.

For more information about Lialda and for Full Prescribing Information, please
'/>"/>

1

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Some patients may not need insulin for long-term control of type 2 diabetes
2. New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
3. Social Security Statement Advises Seniors to Consider Private Long-Term Care Insurance, LTC Agency Reports; Medicare Wont Cover It
4. Treatment at an AASM accredited sleep center improves long-term CPAP compliance
5. Poor sleep a problem in long-term breast cancer survivors
6. Long-term pesticide exposure may increase risk of diabetes
7. Long-term bouts with hay fever worsen ability to breathe through your nose
8. Keane Wins $1.5 Million Electronic Medical Record (EMR) Implementation with Leading Long-Term Care Company
9. Long-term hormone replacement therapy increases breast cancer risk
10. Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
11. Long-term cognitive decline in bypass patients not due to surgery

Post Your Comments:

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading ...(sigmoidoscopy score of less than or equa...),Health